<< Back To Authors

Overview

Benjamin Ryan

Former Editor-at-Large for POZ and its sister publications Hep, Cancer Health and Real Health, where he covers the science of HIV, hepatitis C and cancer. He has also written for The New York Times, The Guardian, New York, The Nation, The Atlantic, The Marshall Project, The Village Voice, The New York Observer, Men's Journal, City & State, Quartz, Out and The Advocate.

Articles

HIV Death Rate Drops

Between 2010 and 2017, the HIV-related death rate fell by half.

Antiretrovirals Don’t Stop Cell Aging

People with untreated HIV in a recent study had signs of faster cell aging, which treatment reduced but did not eliminate.

New Tenofovir Tied to Weight Gain

A recent study sheds light on weight gain after switching to new form of tenofovir.

illustration head puzzle pieces coming apart

HIV Treatment Lowers Early Alzheimer’s Risk

While people with HIV have a higher rate of early Alzheimer’s than those without the virus, treatment appears to eliminate this excess risk.

vaccnie viles and needle going into vial

More Good News About Injectable Treatment

A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.

Islatravir-Based Treatment Shows Promise

The HIV regimen failed only a few study participants.

Fatty Liver Disease and Diabetes

A recent study links diabetes to advanced liver damage in people with HIV.

black woman getting blood pressure taken

Among Women, HIV Is Tied to Chronic Health Conditions

High blood pressure, diabetes, lung disease and cardiovascular disease are all more prevalent among women with HIV.

Hot topics

Forums: Support and discussion

Blogs: The community speaks

POZ Stories: Get inspired

Magazine: Search the archives

HIV: The Basics

Recursos de VIH/SIDA en Español

AIDS Is Everyday

Ask POZ

In Scotland, PrEP Is Tied to Population-Level Decline in HIV

Researchers found that Truvada as pre-exposure prophylaxis greatly reduced HIV cases in both people on PrEP and those not on it.

HPV Vaccine Prompts Good Immune Response in Youths With HIV

A recent study analyzed immune responses to the HPV vaccine among HIV-positive youths 7 to 20 years old.

Integrase Inhibitors Tied to Weight Gain and Hyperglycemia or Diabetes

The antiretroviral drug class includes bictegravir, dolutegravir, elvitegravir and raltegravir.

HIV Vaccine Trial Participants Benefit Socially From Their Efforts

A survey of 6,500 HIV vaccine trial participants found that the good feeling involved with being altruistic was a major benefit.

For Immigrant Mothers With HIV, Bottle-Feeding Guidance May Be Confusing

This finding comes from a small focus group of mothers living with HIV in Canada, most of them born in low-income nations.

Drug-Related Deaths More Likely Stimulant-Linked in San Franciscans With HIV

A study of drug- and alcohol-related deaths in San Francisco reveal stark differences between people with and without HIV.

Africans With Efavirenz-Resistant HIV Have Less Success on Dolutegravir

This finding among sub-Saharan Africans is quite concerning since dolutegravir is now the preferred first-line HIV treatment worldwide.

CRISPR Snips Simian HIV From of Monkeys’ Cells, Even From Viral Reservoir

Trials for HIV-positive people of a treatment using the CRISPR-Cas9 gene editing tool may be on the horizon.